Current Cancer Therapy Reviews - Volume 13, Issue 2, 2017

Background: Malignant mesothelioma is a largely incurable disease that is refractory to current therapies. CD26 is a multifunctional cell surface protein involved in autoimmune disease, diabetes, and cancer. It has a role in T cell function, extracellular protein modification, as a prognostic factor for cancer, and as a therapeutic target for malignant mesothelioma. New treatment strategies are urgently needed for malignant Read More

Background: Currently, existing regimens of genotoxic drugs have been suggested to be complemented with molecular inhibitors as combinatorial and cocktail approaches in malignancy. Methods: In the last decade, attempts have been reported to test several new class of anticancer drug such as miRNA mimetics, RNA enzymes, small molecular inhibitors, DNA repair protein inhibitors and peptide mimetics. Results: With the adve Read More

Background: Phosphodiesterase-5 (PDE5) inhibitors demonstrate off-label anticancer properties, acting through a variety of mechanisms that ultimately reduce tumor proliferation. Method: Combining PDE5 inhibitors with other anti-oncotic agents further enhances their effectiveness against tumors. Mechanistically, PDE5 inhibitors have been shown to inhibit ATP binding cassette (ABC) transporter protein activity, pote Read More

Background: T cell activation via the blockade of PD-1 pathway has been recognized as an emerging drug target for cancer immunotherapy which provides a rationale for clinical trials in cancer patients. The recent breakthrough approvals of T cell checkpoint inhibitors targeting PD-1 pathway boost the era of immuno-oncology drugs. Methods: The progress of PD-1 checkpoint inhibitor as a single agent in the field of immuno-on Read More

Background: Laryngeal cancers affect one quarter of all head and neck cancers. Chemotherapy is a standard method in treatment laryngeal carcinoma. However, cancer chemotherapy is often a failure due to the appearance of drug resistance. This fact suggests that the search for novel, safe, and more effective laryngeal cancer drugs are required. Antimycin A3 is a fit ligand of anti-apoptotic Bcl-2. While Bcl-2 is kn Read More